ESMO 2020 Virtual congress


18 - 22 septembre

L’ESMO 2020 se tiendra en un format virtuel du 18 au 22 septembre 2020.

L'IFCT y sera représenté avec deux communications orales et 3 posters.

Oral presentationNeoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): preliminary results from a a multicenter study (IFCT-1601 IONESCO). 
M. Wislez

Mini oral presentation : The GCO-002 CACOVID-19 cohort: a French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management
A. Lièvre

E-posters :

Lorlatinib for advanced ROS1+ Non-Small Cell Lung Cancer (NSCLC): efficacy and safety data from IFCT-1803Lorlatinib for advanced ROS1+ Non-Small Cell Lung Cancer (NSCLC): efficacy and safety data from IFCT-1803 LORLATU Expanded Access Program (EAP) cohort.
N. Girard

IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cellIFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small celllung cancer (NSCLC)
A. Lavole

Autoimmune diseases in centrally reviewed Thymic Epithelial Tumors (TET)
JC. Benitez 

L'IFCT à l'ESMO 2019 (Barcelona)

Poster session

1591TiP - IFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab induction treatment
Date: 28.09.2019
Time : 12:00 - 13:00
Location: Poster Area (Hall 4)
Speaker: Gerard Zalcman


Oral session

1841O - Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
Date: 30.09.2019
Time : 10:15 - 11:45
Location: Pamplona Auditorium (Hall 2)onday 10:27 - 10:39
Speaker: Gerard Zalcman


L'IFCT à l'ESMO 2018 (Munich).

Download our press release 

Communications orales

A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 Trial
J.-L. Pujol 
21.10.2018 - Hall A1 - Room 17 - 10:00 - 10:15

Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced nonsmall cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase 3 trial
E. Quoix
22.10.2018 Hall A1 - Room 17 - 10:30 - 10:45


Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study.
H. Blons 
20.10.2018  - Hall A3 - Poster Area Networking Hub
View poster

Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): results from phase II trial (IFCT-1001 CHIVA)
M. Wislez 
20.10.2018  - Hall A3 - Poster Area Networking Hub
View poster


L'IFCT à l'ESMO 2017 (Madrid)

Communications orales

Results of the phase III IFCT-0302 trial assessing minimal versus CT-scan-based follow-up for completely resected non-small cell lung cancer (NSCLC)
V. Westeel
View abstract
Download the ESMO press release and the IFCT press release

Second or 3rd line Nivolumab (Nivo) versus Nivo plus Ipilimumab (Ipi) in Malignant Pleural Mesothelioma (MPM) patients: updated results of the IFCT-1501 MAPS2 randomized phase 2 trial.
G. Zalcman
Download the abstract and the IFCT/AP-HP press release in FR end EN

Posters Discussion

IFCT-1502 CLINIVO: Real-life experience with nivolumab in 600 patients with advanced Non-Small Cell Lung Cancer (NSCLC): efficacy and safety of nivolumab and post-nivolumab treatment in the French Expanded Access Program (EAP)
N. Girard
View abstract
View poster

Ultrasensitive detection of EGFR T790M mutation by droplet digital PCR (ddPCR) in TKI naïve non-small cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide program Biomarkers France of the French Cooperative Thoracic Intergroup (IFCT).
C. Leduc
View abstract
View poster

Voir le site du congrès en cliquant ici.


L'IFCT à l'ESMO 2016

ESMO 2016 banner

Notre étude Biomarqueurs France était une nouvelle fois à l’honneur à l’ESMO (Copenhague) du 7 au 11 octobre avec une communication orale sur une étude ancillaire concernant l’épidémiologie moléculaire des mutations dans le CBNPC :

Clinical and biological characteristics of non-small cell lung cancer (NSCLC) harbouring EGFR mutation : Results of the nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) (C. Leduc)   Abstract

Les études PREDICT.amm, RYTHMIC, STIMULI et IFCT-1003 LADIE seront aussi présentées à l'ESMO :

Posters discussion :
- Cost-effectiveness of KRAS, EGFR and ALK testing for therapeutic decision making of advanced stage non-small cell lung cancer (NSCLC) : The French IFCT-PREDICT.amm study (A. Drezet) Abstract
- Pathological central review of 400 thymic epithelial tumors (TET) : The national network RYTHMIC experience (T. Molina)  Abstract
- Quality of resection and outcome in stage III thymic epithelial tumors (TET) : A retrospective analysis of 150 cases from the national network RYTHMIC experience (M. Bluthgen)  Abstract

Posters :
- STIMULI : A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after standard of care chemo-radiotherapy conducted by ETOP and IFCT (D. De Ruysscher) Abstract
- IFCT-1003 LADIE trial : Randomized phase II trial evaluating treatment with EGFR-TKI versus EGFR-TKI associated with anti-estrogen in women with non-squamous advanced stage NSCLC (J. Mazières)

Voir le site du congrès :

Télécharger les pièces jointes :
Lu 9703 fois Dernière modification le 21/07/2020